Recombinant Botulinum Peptide Cross-Linking for Vaccine Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for botulinum, tetanus, and Clostridium difficile toxins face challenges such as reduced immunogenicity due to protein modification by formaldehyde, leading to aggregation and decreased stability, and require separate vaccines for each serotype and subtype, which complicates cross-protection.
Innovation Solution
A process involving recombinant non-toxic bacterial peptides, such as the LH N fragment of botulinum neurotoxin or Clostridium difficile toxins, are chemically modified with formaldehyde to introduce intra-molecular cross-linking, enhancing immunogenicity and stability without significant aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If formaldehyde is used to inactivate toxins for vaccine production, then the neurotoxic action is eliminated, but the immunogenicity is reduced and protein aggregation occurs
Solution Approach 1:
The toxin is divided into separate functional domains (HC fragment for receptor binding, HN fragment for translocation, and LC fragment for enzymatic activity). The vaccine uses the HC fragment alone, which retains immunogenicity while lacking toxic enzymatic activity, thus avoiding the need for formaldehyde inactivation and the associated immunogenicity loss and aggregation problems
Solution Approach 2:
The toxic light chain (LC) fragment containing the zinc-dependent endopeptidase activity is removed from the toxin structure. The remaining heavy chain (HC) fragment retains the ability to bind receptors and elicit immune response but lacks the toxic catalytic domain, providing a safe alternative to formaldehyde-inactivated whole toxin
2Object-affected harmful factors
If formaldehyde treatment is applied to detoxify toxins, then toxicity is reduced, but protein structure is modified and immunogenic epitopes are lost
Solution Approach 1:
The natural functional separation of the toxin into HC and LC fragments connected by disulfide bonds is exploited. The HC fragment, which naturally lacks enzymatic activity, is isolated and used as the vaccine antigen. This converts the structural complexity of the whole toxin into a benefit by using only the immunogenic, non-toxic portion, avoiding formaldehyde-induced epitope destruction
Solution Approach 2:
A recombinant version of the HC fragment is produced using molecular biology techniques. This recombinant HC fragment serves as a precise copy of the natural immunogenic domain without the toxic LC portion, providing a stable, aggregation-free vaccine antigen that preserves all immunogenic epitopes
3Reliability
If separate vaccines are developed for each botulinum serotype, then specific protection is achieved, but vaccine complexity and the number of required vaccines increase
Solution Approach 1:
The HC fragment structure is highly conserved across all seven botulinum neurotoxin serotypes (A-G), with greater than 90% sequence identity in the receptor-binding domain. A single vaccine formulation using the HC fragment provides cross-protection against all serotypes, eliminating the need for seven separate vaccines while maintaining specific protection through the conserved immunogenic epitopes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chemical modification increases the protective effect of the peptides by improving immune response, cross-serotype, and cross-subtype protection, and stability, resulting in more effective vaccines with improved immunogenicity and stability.
Implementation Method 1
exposing the recombinant non-toxic bacterial peptide to 0.2% formaldehyde at 35°C for 24 hours, to introduce intra-molecular cross-linking into the recombinant non-toxic bacterial peptide
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides compositions comprising an antigenic peptide, wherein the peptide has been treated with a chemical modifying agent to improve its ability to stimulate an immune response. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a vaccine.